HEALTHCARE REFORM AND DISCLOSURE LEGISLATION
Understanding the Factors Prompting Federal and State Disclosure Legislation and Determining How a Perceived Increase in Transparency will Impact the Industry and American Health Care System
Richard F. Eschle, Pharm.D., Director, Regulatory Compliance, NOVARTIS

FEDERAL KEYNOTE ADDRESS: LEGISLATIVE UPDATE
Reviewing the Progress and Details of Federal Disclosure Legislation to Guide Your Company’s Tracking and Reporting Efforts
Christopher J. Armstrong, Esq., Investigative Counsel, COMMITTEE ON FINANCE, THE OFFICE OF THE HONORABLE CHARLES GRASSLEY, RANKING MEMBER, UNITED STATES SENATE, WASHINGTON, DC

MASSACHUSETTS DISCLOSURE LAW
Exploring the Massachusetts Disclosure Legislation and the Associated Impact on Reporting Five Months Since the July 1, 2009 Implementation Deadline
Melissa J. Lopes, Deputy General Counsel, DEPARTMENT OF PUBLIC HEALTH, MASSACHUSETTS

CLINICAL INVESTIGATOR PAYMENTS
Breaking Down Silos to Work Effectively with R&D in Capturing and Disclosing Investigator Payment Information
Shannon Thyme Klinger, Senior Vice President and General Counsel NAFTA, SOLVAY PHARMACEUTICALS